Articles By Anuja Singh
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage…
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled to report its…
ByWill Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…
Why Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
Roche Signals Dual Growth Strategy: Price Reform Alignment in the U.S. and Aggressive Expansion…
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for its next growth…
Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Could Amgen’s 340B Pricing Practices Face Legal and Market Scrutiny?
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage…
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled to report its…
Will Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…
Why Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
Roche Signals Dual Growth Strategy: Price Reform Alignment in the U.S. and Aggressive Expansion…
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for its next growth…
Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Could Amgen’s 340B Pricing Practices Face Legal and Market Scrutiny?
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…